IFIT-5 rabbit pAb from ELK Biotechnology Read more ›
IFIT-5 rabbit pAb is a research-use antibody from ELK Biotechnology for studying IFIT-5 in WB, ELISA workflows with listed reactivity for Human, Rat, Mouse. Specifications and supporting documents below should be reviewed when planning the experiment.
induction:By interferons.,similarity:Belongs to the IFIT family.,similarity:Contains 8 TPR repeats.,
| Specificity | IFIT-5 Polyclonal Antibody detects endogenous levels of IFIT-5 protein. |
|---|---|
| Validation evidence captions | Western blot analysis of the lysates from HepG2 cells using IFIT5 antibody. |
| Collaborator | ELK Biotechnology |
| Partner model | ES5393 |
| Target | IFIT-5 |
| Research areas | Antibody Research |
| Reactivity | Human,Rat,Mouse |
| Applications | WB,ELISA |
| Conjugation | Unconjugated |
| Dilution range | Western Blot: 1/500 - 1/2000. ELISA: 1/40000. Not yet tested in other applications. |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Immunogen | The antiserum was produced against synthesized peptide derived from human IFIT5. AA range:281-330 |
| Concentration | 1 mg/ml |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Assay type | Antibody validation/application |
| Expression system | Pancreas,Spleen, |
| Purity | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Species | WB | IHC | IF | ELISA | IP | FCM | ChIP |
|---|---|---|---|---|---|---|---|
| Human | |||||||
| Rat | |||||||
| Mouse |
| Species | Dilution | Notes |
|---|---|---|
| Human | Western Blot: 1/500 - 1/2000. ELISA: 1/40000. Not yet tested in other applications. | — |
| Rat | — | — |
| Mouse | — | — |
| Species | Dilution | Notes |
|---|
Collaborator meets ABMIUM quality standards and overall product performance standards have been met.
Quality management certification.
For research applications. Not for diagnostic use.
No customer reviews yet.
